MCS secures FDA approval of patient monitoring app with mobile compression therapy device

9 August 2016 (Last Updated August 9th, 2016 18:30)

Israel-based MCS Medical Compression Systems’ US subsidiary MCS has secured the US Food and drug Administration (FDA) approval for its monitoring application along with ActiveCare, a device for deep vein thrombosis (DVT) prevention.

Israel-based MCS Medical Compression Systems’ US subsidiary MCS has secured the US Food and drug Administration (FDA) approval for its monitoring application along with ActiveCare, a device for deep vein thrombosis (DVT) prevention.

ActiveCare product line features wearable, non-invasive smart compression therapy devices designed to improve arterial, venous and lymphatic circulation and result to improved clinical benefit along with economic value.

The ActiveCare Online platform is fitted with Bluetooth which facilitates data transmission in a wireless way through an application installed on the patient’s smartphone relayed to their healthcare providers.

"ActiveCare Online will allow hospitals to better communicate with and monitor patients during CMS's required post discharge 90-day period."

It is a portable, lightweight device that remains with the patient from the hospital throughout rehabilitation to home.

The ActiveCare Online uses synchronised flow technology (SFT) to result an effective and safe DVT prevention during and after surgery.

MCS CEO and board vice-chairman Gerry Feldman said: "This news provides an immediate opportunity to improve post-surgical outcomes and patient satisfaction following surgery, by monitoring and improving patient compliance with therapy.

“Better outcomes reducing complications and readmissions are expected to result in substantial cost savings to institutions, all of which can help hospitals to excel in the CJR programme.

“ActiveCare Online will allow hospitals to better communicate with and monitor patients during CMS's required post discharge 90-day period."

The access to this application, following the FDA clearance, is expected to enable hospitals and caregivers to achieve better results fulfilling the criteria of CMS's new bundled payment Comprehensive Care for Joint Replacement (CJR) programme, which financially rewards institutions who exhibit improved patient outcomes.